Or
Contact UsMelphalan comes up most often in conversations about multiple myeloma. It also has a role before autologous stem cell transplantation.
The drug works inside the bone marrow. It reduces the activity of abnormal plasma cells — the ones that drive the disease and crowd out healthy blood production.
In one patient, melphalan may be part of a standard treatment course. In another, it is the step that prepares the body before returning the patient’s own stem cells. Same name, different purpose.
This is not a drug that gets added just in case. Before it starts, the doctor needs to know whether the patient can carry the load — kidney function, blood counts, prior treatment, and what the goal of therapy is right now.
Inside a cancer cell, melphalan disrupts the DNA so the cell loses its ability to copy itself. Division stalls. The cell cannot move forward and eventually stops reproducing.
But healthy tissue responds too. The bone marrow is particularly sensitive. Blood cell counts can drop, sometimes significantly. That is why the starting point matters — what are the numbers before treatment begins, and is there room to carry this safely.
The doctor is not only thinking about the dose. Preparation, timing of lab checks, condition of the mouth lining, kidney function, and the ability to support the patient through a difficult recovery — all of that is part of the plan.
Melphalan appears in treatment plans across several diagnoses, most of them connected to plasma cells and bone marrow. It may come up in cases of:
A diagnosis alone does not make melphalan the right answer. The doctor looks at age, bone marrow reserve, kidney numbers, what treatment has already been done, and what the current goal actually is.
Melphalan is usually discussed when there is a defined task, not simply to add another drug to the plan. It tends to come up when:
The real question is not whether melphalan can be prescribed. It is what specific job it is supposed to do right now — transplant preparation, disease control, or part of a larger plan that has its own logic.
The hematologist needs more than a diagnosis and old records before making a decision about melphalan. Details that seem minor can change the clinical picture entirely.
Sometimes one result changes everything. Low neutrophils, an active infection, poor kidney function, or too short a gap since the last treatment — any of these can shift the decision. It is not a formality. Safety depends on it.
Melphalan can be given in more than one way. Some patients take it as tablets or receive a standard intravenous infusion. Others receive it at a much higher dose as part of a transplant program, before their own stem cells are returned.
Before treatment begins, it is important to understand not just the drug name but the full scenario — standard course, transplant preparation, or an individual step after prior therapy. That affects the dose, the monitoring, and what the recovery period looks like.
During treatment the team monitors:
When melphalan is used at high doses, the hardest days often come after the infusion rather than during it. The bone marrow is temporarily suppressed. The patient needs close monitoring, fast access to the medical team, and support if complications arise.
Melphalan can fit well into a myeloma plan, but fitting well is not the same as easy to carry. Blood counts, mucous membranes, and infection risk tend to need the most attention.
At high doses, mucous membrane reactions and blood count drops can be significant. Knowing in advance where monitoring happens and how quickly the doctor can be reached is not a detail — it is part of the plan.
Some symptoms during melphalan treatment should not wait for the next scheduled visit. Contact the medical team the same day if any of the following appear:
When neutrophil counts are low, an infection can move fast. What looks like a simple fever is a reason to call the doctor right away, not a reason to wait and see.
Melphalan does not automatically fit every patient with multiple myeloma. The tumor may match the drug while the patient’s body does not. Several factors shape whether it is a safe option:
Sometimes the doctor chooses a different drug or delays the start. The risk of complications at that moment is higher than the expected benefit. That is not a refusal to help. It is a choice of the safer path.
Yes, and it often is. In hematologic oncology, melphalan can be part of a combination regimen. But the combination needs a clear purpose — not just intensity for its own sake. It may be discussed alongside:
The more complex the regimen, the more important it is to monitor lab results and how the patient is feeling throughout. A stronger plan is not automatically a better one if the patient cannot safely carry it through.
Melphalan does not always give a clear answer fast. First comes the period when blood counts fall and then recover. Only after that does it become clearer how the disease has responded.
In multiple myeloma, the doctor does not rely on a single test. Protein markers, blood counts, kidney function, bone marrow findings, the patient’s symptoms, and how the body is coming out of the course — all of these together give a real picture.
When treatment is connected to a transplant, the first weeks often look more like recovery from a serious hit than a time for conclusions. That is hard for the patient and the family. It does not automatically mean something is going wrong.
Tel Aviv Medical Clinic offers hematology consultations for patients facing decisions about melphalan — particularly in multiple myeloma, transplant preparation, or when the choice of the next treatment line is not straightforward.
A consultation can help when:
We do not step in as the treating physician and do not prescribe therapy by correspondence. Our role is to help the patient and family understand the medical reasoning behind the decision and walk into the next conversation prepared.
It is most often discussed for myeloma. But in hematology there are other situations where the drug appears in a treatment plan. I would not draw conclusions from the diagnosis name alone. The important thing is understanding what the doctor is trying to achieve — a standard course, transplant preparation, managing a relapse, or something more individual.
It is chemotherapy. The difference is in where and for what purpose it is used. In myeloma, melphalan can be part of a very specific strategy. At high doses before a transplant it is no longer just another drug — it is a step that prepares the body for the return of the patient’s own cells.
Because the bone marrow is one of the main areas of risk. If counts are already low, the treatment becomes more dangerous. I look at more than hemoglobin — neutrophils, platelets, trends over time, and how quickly the patient recovered after prior therapy.
Sometimes yes, but the decision needs care. In myeloma, kidney function often plays a significant role and can affect which regimen is safe. You cannot go by creatinine alone. The full picture matters — degree of impairment, cause, other medications, hydration status, disease activity, and what the treatment is supposed to accomplish.
Because the drug can suppress the bone marrow substantially. This is especially true in high-dose treatment. White blood cells, platelets, and hemoglobin can all fall during that period. The patient becomes more vulnerable to infection and bleeding. Monitoring after the infusion is just as important as the infusion itself.
No. Sometimes it is used in a transplant context. Other times it appears in a different regimen entirely. I always clarify which protocol is being discussed. The same drug name can mean very different doses, different risks, and a different treatment goal.
Contact the doctor right away. After melphalan, a fever is not something to wait out, especially when blood counts are low. Sometimes it is not days but hours that matter. It is always better to call one extra time than to miss an infection when neutrophils are down.
This page gives general medical information. It is not a personal treatment plan. The decision to use melphalan is made by a hematologist after reviewing the diagnosis, lab results, kidney function, prior therapy, the patient’s overall condition, and what the treatment is meant to achieve.
Do not start, stop or change treatment without your treating physician.
For consultation about melphalan treatment:
📞 +972-73-374-6844
💬 WhatsApp: +972-52-337-3108
